Propanc Biopharma Advances First-in-Human Trial for PRP Cancer Therapy — Propanc Biopharma, Inc.

Event summary

Propanc Biopharma has commenced finalizing the clinical trial protocol for a Phase 1b study of PRP in up to 40 advanced cancer patients with solid tumors.
The study will be led by Avance Clinical Pty Ltd and involve a feasibility assessment across multiple clinical trial centers in Australia.
The Phase 1b study is designed as a two-part, open-label, dose escalation and dose expansion study to evaluate the safety, tolerability, and preliminary activity of PRP.
The Clinical Trial Application (CTA) submission is planned for Q4 2026.

The big picture

Propanc Biopharma's advancement of the Phase 1b clinical study for PRP represents a significant step in the development of a first-in-class therapy targeting metastatic cancer. The study's focus on safety, tolerability, and preliminary activity aligns with broader industry trends towards personalized and targeted cancer treatments. The company's long-term research and development efforts, spanning nearly two decades, underscore the strategic importance of this milestone in the competitive landscape of oncology therapies.

What we're watching

Clinical Trial Execution: The pace at which Propanc Biopharma can finalize the clinical trial protocol and obtain feedback from investigators will determine the timeline for CTA submission.
Regulatory Approval: The success of the Phase 1b study and the subsequent regulatory approval process will be critical for the future development and commercialization of PRP.
Market Interest: The level of anticipatory interest among the medical and scientific communities will impact the company's ability to attract partners and investors.